Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports

Similar Items

• Assessing taxane-associated adverse events using the FDA adverse event reporting system database
  by: Dong-Hui Lao, et al.
  Published: (2021-06-01)
• Primary Occipital Ewing’s Sarcoma with Subsequent Spinal Seeding
  by: Ali Alqahtani, et al.
  Published: (2017-01-01)
• Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system.
  by: Akiho Fukuda, et al.
  Published: (2017-01-01)
• Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
  by: Toshiyuki Sakaeda, et al.
  Published: (2011-01-01)
• Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
  by: Long Meng, et al.
  Published: (2021-02-01)